There remains no appropriate parameter for predicting the response of glioblastoma to bevacizumab as precisely as epidermal growth factor receptor (EGFR) mutation predicts the response to tyrosine kinase inhibitor (TKI) treatment (16, 17). This evidence concerns the gene EGFR and glioblastoma.